2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide
2022.1.0 - CI Build

2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide, published by Centers for Disease Control and Prevention (CDC). This guide is not an authorized publication; it is the continuous build for version 2022.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/opioid-cds-r4/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 2022 CDC Clinical Practice Guideline - Profiles
... 3 2022 CDC Clinical Practice Guideline - Terminology
... 4 2022 CDC Clinical Practice Guideline - Examples
... 5 2022 CDC Clinical Practice Guideline - Documentation
.... 5.1 2022 CDC Clinical Practice Guideline - Process Documentation
... 6 2022 CDC Clinical Practice Guideline - Downloads
... 7 2022 CDC Clinical Practice Guideline - User Interaction Alerts
... 8 2022 CDC Clinical Practice Guideline - Subroutines
... 9 2022 CDC Clinical Practice Guideline - Acute Pain
... 10 Chronic Pain Decision Documentation
... 11 Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration
... 12 Recommendation #2 - Prioritize Nonopioid Pain Therapies
... 13 Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy
... 14 Recommendations #4 and #5 - Lowest Effective Dose
... 15 Recommendation #6 - Prescribe Lowest Effective Dose and Duration
... 16 Recommendation #7 - Opioid Therapy Risk Assessment
... 17 Recommendation #8 - Naloxone Consideration
... 18 Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions
... 19 Recommendation #10 - Urine Drug Testing
... 20 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines
... 21 Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder
... 22 License and Legal Terms
... 23 Artifacts Summary
.... 23.1 HelloWorld
.... 23.2 HelloWorldPatientView
.... 23.3 CDCMMEClinicalConversionFactors
.... 23.4 OpioidCDSRoutines
.... 23.5 OpioidCDSCommon
.... 23.6 OpioidCDSCommonConfig
.... 23.7 OpioidLogicMK2020
.... 23.8 OpioidData2020
.... 23.9 FHIRHelpers
.... 23.10 FHIRModelInfo
.... 23.11 OpioidCDSREC10CommonLibrary
.... 23.12 OpioidCDSREC01Library
.... 23.13 OpioidCDSREC02Library
.... 23.14 OpioidCDSREC03Library
.... 23.15 OpioidCDSREC04And05Library
.... 23.16 OpioidCDSREC06Library
.... 23.17 OpioidCDSREC07Library
.... 23.18 OpioidCDSREC08Library
.... 23.19 OpioidCDSREC09Library
.... 23.20 OpioidCDSREC10OrderSignLibrary
.... 23.21 OpioidCDSREC10PatientViewLibrary
.... 23.22 OpioidCDSREC11OrderSelectLibrary
.... 23.23 OpioidCDSREC11PatientViewLibrary
.... 23.24 OpioidCDSREC12PatientViewLibrary
.... 23.25 OpioidRiskAssessmentActivityDefinition
.... 23.26 OpioidUrineScreeningActivityDefinition
.... 23.27 OpioidUrineScreeningActivityDefinition
.... 23.28 OpioidUrineScreeningActivityDefinition
.... 23.29 Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration
..... 23.29.1 Library
.... 23.30 Recommendation #2 - Opioid Therapy Goals Discussion
..... 23.30.1 Library
.... 23.31 Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy
..... 23.31.1 Library
.... 23.32 Recommendations #4 and #5 - Lowest Effective Dose
..... 23.32.1 Library
.... 23.33 Recommendation #6 - Prescribe Lowest Effective Dose and Duration
..... 23.33.1 Library
.... 23.34 Recommendation #7 - Opioid Therapy Risk Assessment
..... 23.34.1 Library
.... 23.35 Recommendation #8 - Naloxone Consideration
..... 23.35.1 Library
.... 23.36 Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions
..... 23.36.1 Library
.... 23.37 Recommendation #10 - Urine Drug Testing (order-sign)
..... 23.37.1 Library
.... 23.38 Recommendation #10 - Urine Drug Testing (patient-view)
..... 23.38.1 Library
.... 23.39 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines (order-select)
..... 23.39.1 Library
.... 23.40 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines (patient-view)
..... 23.40.1 Library
.... 23.41 Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder (patient-view)
..... 23.41.1 Library
.... 23.42 Morphine Milligram Equivalent (MME) Conversion Factors for FHIR R4
.... 23.43 Morphine Milligram Equivalent (MME) Calculator for FHIR R4
.... 23.44 Opioid Management Terminology Knowledge Data
.... 23.45 Opioid Management Terminology Knowledge Logic
.... 23.46 CDC_ValueSet
.... 23.47 DataDateRollerExtension
.... 23.48 CDC 2022 Opioid Guidance Clinical Focus Extension
.... 23.49 CDC 2022 Opioid Guidance Data Element Extension
.... 23.50 CDC 2022 Opioid Guidance exclusion Criteria Extension
.... 23.51 CDC 2022 Opioid Guidance Inclusion Criteria Extension
.... 23.52 Barbiturate urine drug screening tests
.... 23.53 Benzodiazepine urine drug screening tests
.... 23.54 Buprenorphine urine drug screening tests
.... 23.55 Heroin urine drug screening tests
.... 23.56 Oxycodone urine drug screening tests
.... 23.57 ValueSet - Medication Request Category Community
.... 23.58 ValueSet - Medication Request Status Active
.... 23.59 CodeSystem - CDC 2022 Opioid Indicator
.... 23.60 CDC Opioid Override Reasons
.... 23.61 OpioidCDS CarePlan
.... 23.62 Cancer Diagnosis Condition
.... 23.63 End of Life Condition
.... 23.64 Terminal Condition
.... 23.65 Cancer Diagnosis Encounter
.... 23.66 Oncology Participant Encounter
.... 23.67 Ambulatory Opioid MedicationDispense
.... 23.68 OpioidCDS MedicationRequest
.... 23.69 Ambulatory Opioid MedicationRequest
.... 23.70 OpioidCDS Observation
.... 23.71 OpioidCDS Patient
.... 23.72 Oncology Specialist PractitionerRole
.... 23.73 OpioidCDS RequestGroup
.... 23.74 Palliative Care ServiceRequest
.... 23.75 All urine drug screening tests
.... 23.76 Amphetamine-class drugs and metabolite urine tests
.... 23.77 Amphetamine class medications
.... 23.78 Barbiturate Medications
.... 23.79 Benzodiazepine medications
.... 23.80 Buprenorphine and Methadone medications
.... 23.81 Buprenorphine Medications
.... 23.82 Cannabinoid class urine drug screening
.... 23.83 CDC malignant cancer conditions
.... 23.84 CNS depressant medications
.... 23.85 Cocaine urine drug screening tests
.... 23.86 Sleep disordered breathing
.... 23.87 Conditions documenting substance misuse
.... 23.88 Conditions likely terminal for opioid prescribing
.... 23.89 Extended release opioid with ambulatory misuse potential
.... 23.90 Fentanyl-type medications
.... 23.91 Fentanyl-type urine drug screening tests
.... 23.92 General opiate urine drug screening tests
.... 23.93 Hospice Finding
.... 23.94 Hospice Procedure
.... 23.95 Limited life expectancy conditions
.... 23.96 Methadone medications
.... 23.97 Methadone urine drug screening tests
.... 23.98 Naloxone medications
.... 23.99 Non-opioid drug urine screening
.... 23.100 Non-synthetic opioid medications
.... 23.101 Oncology specialty designations (NUCC)
.... 23.102 Opiate specific urine drug screening tests
.... 23.103 Opioid analgesics with ambulatory misuse potential
.... 23.104 Opioid counseling procedure
.... 23.105 Opioid misuse assessment procedure
.... 23.106 Opioid misuse disorders
.... 23.107 Opioid treatment assessment procedure
.... 23.108 Opioid drug urine screening
.... 23.109 Oxycodone Medications
.... 23.110 Pain management procedure
.... 23.111 Pain treatment plan
.... 23.112 PDMP data reviewed finding
.... 23.113 PDMP review procedure
.... 23.114 Phencyclidine urine drug screening tests
.... 23.115 Sickle-cell diseases
.... 23.116 Substance misuse behavioral counseling
.... 23.117 Synthetic opioid medications
.... 23.118 Synthetic opioid urine drug screening tests
.... 23.119 Therapies indicating end of life care
.... 23.120 Condition Clinical Status Active
.... 23.121 Encounter Diagnosis Condition Category
.... 23.122 Problem List Condition Category
.... 23.123 US Core Health Concern Condition Category
.... 23.124 Hospice Disposition
.... 23.125 Observation Category Laboratory
.... 23.126 Observation Category Procedure
.... 23.127 Office Visit
.... 23.128 Xylazine drug urine screening tests
.... 23.129 CQFToolingDevice